Phase 1b safety test of IMSB301 for people with Type 1 interferonopathies

A Phase 1b Open-Label Study of IMSB301 in Subjects With a Type 1 Interferonopathy

This trial tests whether IMSB301 is safe and well tolerated when given alone to people with genetically confirmed Type 1 interferonopathies.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (estimated)
• Ages: 12 Years and up
• Sex: All
• Sponsor: ImmuneSensor Therapeutics Inc. (Industry-sponsored)
• Locations: 1 site (Sydney)
• Trial ID: NCT07364513 on ClinicalTrials.gov

What this trial studies

This open-label Phase Ib trial gives IMSB301 as monotherapy to patients with molecularly confirmed Type 1 interferonopathies to characterize safety and tolerability. Dosing uses the recommended Phase Ib dose from a prior Phase Ia, with the first dose given on Day 1 under observation for at least six hours and subsequent home dosing approximately every 12 hours. Participants attend weekly outpatient visits on Days 8, 15, 22 and 29, with follow-up visits on Days 36, 43 and 57; continued treatment beyond Day 28 may be allowed case-by-case for those judged to benefit. Key eligibility requires specific genetic diagnoses and minimum age/weight thresholds described in the protocol.

Who should consider this trial

Good fit: Ideal candidates are people with a molecular diagnosis of one of the listed Type 1 interferonopathies (for example AGS with specified gene mutations, monogenic SLE with listed mutations, familial chilblain lupus, COPA syndrome, DNASE2-related interferonopathy, or ATAD3A-related neurological syndrome) who meet the age, weight, and clinical criteria in the protocol.

Not a fit: Patients without the specified genetic mutations or with other interferonopathy subtypes not listed, or those unable to meet the age/weight or visit requirements, are unlikely to be eligible or to benefit from this protocol.

Why it matters

Potential benefit: If successful, IMSB301 could reduce harmful type I interferon activity and improve disease-related symptoms in affected patients.

How similar studies have performed: Other therapies that target type I interferon signaling, including JAK inhibitors, have shown benefit in some interferonopathy patients, but IMSB301 is a novel agent with limited prior human data.

Eligibility criteria

Inclusion Criteria:

1. First subject must be at least 16 years of age and weighing at least 50 kg. Remaining subjects must be at least 12 years of age and weighing at least 40 kg.
2. Molecular diagnosis of one of the following:

   1. Aicardi-Goutières Syndrome (AGS) with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, LMS11, or RNU7-11, or
   2. Monogenic SLE with mutations in TREX1, RNASEH2A, RNASEH2B, or RNASEH2C, or
   3. Familial chilblain lupus (CHBL) with mutations in TREX1 or SAMHD1, or
   4. Neurological syndromes with mutations in ATAD3A, or
   5. An unnamed interferonopathy with mutations in DNASE2, or
   6. Coatomer Protein Complex subunit alpha (COPA) syndrome with mutations in COPA. The remaining subtypes of AGS and other type 1 interferonopathies are not eligible.
3. Clinical syndrome consistent with type 1 interferonopathy diagnosis based on clinical, CSF, or radiological findings.
4. Women of child-bearing potential (defined as a female who has experienced menarche and who has not undergone successful surgical sterilization \[hysterectomy, bilateral salpingectomy, or bilateral oophorectomy\]) or is not postmenopausal (defined as amenorrhea for at least 12 consecutive months with an appropriate clinical profile at the appropriate age, e.g., greater than 45 years) must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day -1.
5. Sexually active male and female subjects with reproductive potential must agree to use highly effective contraception or agree to abstain from heterosexual intercourse throughout the study and for at least 3 months after last study drug dose.
6. Subjects and caregiver must be willing and able to comply with scheduled visits, clinical assessments, blood sample collections, and other trial procedures.
7. Have the ability to provide informed consent or have legal representative of minor/vulnerable subjects who is willing and able to provide written informed consent, provided that assent is obtained from subjects at an age-appropriate level.

Exclusion Criteria:

1. Presence of other significant neurological disorder that is not related to type 1 interferonopathy, brain tumor or other space-occupying lesion, or history of severe head injury.
2. The presence of significant concomitant disease that would, in the judgement of the Investigator, pose additional risk to the subject, interfere with the assessment of safety and tolerability, or significantly interfere with the metabolic disposition of study drug.
3. BMI above 33 kg/m2 or a total body weight in excess of 130 kg.
4. Have any of the following infection risks:

   1. Evidence of active infection during screening or on Day 1
   2. Symptomatic herpes zoster infection within 12 weeks prior to the screening period, or more than one episode of herpes zoster infection in the preceding two years
   3. Positive hepatitis B, hepatitis C, HIV or TB test at screening
   4. Household contact with a person with active TB and did not receive appropriate and documented prophylaxis for TB
   5. Serious infection, defined as infection requiring admission to hospital or treatment with intravenously administered medication, within the six months.
5. Resting 12-lead ECG showing confirmed prolongation of QTc (Fridericia's correction) interval (QTc interval \> 470 for females and \>450 for males), or other baseline ECG abnormalities that, in the judgement of the Investigator, would pose additional safety risk to the subject.
6. A prior history of cancer, other than squamous cell carcinoma, basal cell carcinoma, or cervical intra-epithelial neoplasia that was successfully treated at least five years prior to the screening visit and which has shown no sign of clinical recurrence.
7. Receipt of an investigational drug within 30 days or five half-lives of the drug (whichever is longer) prior to Day -1.
8. Prior treatment with an immunomodulator including a JAK inhibitor within 14 days of screening.
9. Prior treatment with an interferon inhibitor within 3 months of screening.
10. Concurrent treatment of a nucleoside reverse transcriptase inhibitor or other antiviral drug.
11. Receipt of a strong inhibitor of CYP3A4 (APPENDIX A) within five half-lives prior to Day -1
12. Known allergy to IMSB301 or its components.
13. Known allergy to shellfish.
14. Female subjects who are breastfeeding or who have a positive pregnancy test at screening or Day -1.
15. Receipt of a vaccination within 3 weeks prior to Day -1.

Where this trial is running

Sydney

• The Children's Hospital at Westmead — Sydney, Australia (Recruiting)

Conditions Type 1 Interferonopathies